Relapsed acute myeloid leukemia drug market is anticipated to grow at a significant CAGR during the forecast period. Acute myeloid leukemia is a blood and bone marrow cancer with excess immature white blood cells. Additionally, relapsed acute myeloid leukemia occurs in patients who do not respond to the first line of treatment. The major factor accelerating the growth of the market is the increasing demand for better treatment options with minimal side effects.
Moreover, the market is also growing due to the increasing prevalence of relapsed acute myeloid leukemia globally. According to the Leukemia Care Organization UK, AML relapse affects about 50% of all patients who achieved remission after initial treatment. Additionally, it may occur several months to several years after treatment. Further, almost all patient carries the risk of relapse with the majority of relapses occurring within two to three years of initial treatment. Hence, the rising rate of relapsed AML is in turn driving the growth of the market.
Some major players operating in the market include AbbVie Inc., Amgen Inc., and Novartis Intetrnational AG, among others. The market players are contributing significantly to the growth of the market by the adoption of various strategies including mergers & acquisitions, geographical expansion, partnerships and collaborations, and new product launches, to stay competitive in the market. For instance, in March 2020, Gilead Sciences, Inc. announced that it will acquire Forty Seven, Inc. for $4.9 billion. The acquisition was aimed to strengthen Gilead’s immuno-oncology research and development portfolio.
To Request a Sample of our Report on Relapsed Acute Myeloid Leukemia Drug Market: https://www.omrglobal.com/request-sample/relapsed-acute-myeloid-leukemia-drug-market
Market Coverage
- The market number available for – 2022-2029
- Base year- 2022
- Forecast period- 2023-2029
Segment Covered-
- By Type
- By Application
Regions Covered-
- North America
- Europe
- Asia-Pacific
- Rest of the World
Competitive Landscape- AbbVie Inc., Amgen Inc., and Novartis Intetrnational AG, among others.
Relapsed Acute Myeloid Leukemia Drug Market Report by Segment
By Type
- aNK Program
- AT-9283
- BI-836858
- Binimetinib
- BL-8040
- Others
By Application
- Clinic
- Hospital
- Others
A full Report of Relapsed Acute Myeloid Leukemia Drug Market is Available @ https://www.omrglobal.com/industry-reports/relapsed-acute-myeloid-leukemia-drug-market
Relapsed Acute Myeloid Leukemia Drug Market Report by Region
North America
- United States
- Canada
Europe
- UK
- Germany
- Spain
- France
- Italy
- Rest of Europe
Asia-Pacific
- India
- China
- Japan
- South Korea
- Rest of APAC
Rest of the World
- Latin America
- Middle East & Africa
Reasons to buy from us –
- We cover more than 15 major industries, further segmented into more than 90 sectors.
- More than 120 countries are for analysis.
- Over 100+ paid data sources mined for investigation.
- Our expert research analysts answer all your questions before and after purchasing your report.
About Orion Market Research
Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services.
Media Contact:
Company Name: Orion Market Research
Contact Person: Mr. Anurag Tiwari
Email: info@omrglobal.com
Contact no: +91 7803040404
